FDA ‘uncertainty’ leads Krystal Biotech to halt cancer drug trial | STAT
Understanding the Impact of FDA Decisions on Biotech Trials In the world of biotechnology, regulatory decisions can have ripple effects that extend beyond the immediate concern. Recently, a notable case involved the FDA’s rejection of a skin cancer therapy developed by Replimune Group. This decision didn’t just affect Replimune; it led to the abrupt pause …